A Phase 2 interventional study of Ruxolitinib cream and Vehicle Cream in Vitiligo, sponsored by Incyte Corporation. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.
Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.
Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 5 in phase 2, and was the 6th registered.
343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.
Browse Vitiligo studies →5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:
Incyte Corporation · Sites in Argentina, Austria, Belgium and 11 more countries
Ages 6–11
Incyte Corporation · Sites in United States, Canada
Ages 2–11
Hospital Authority, Hong Kong · Sites in Hong Kong
Ages 18–85
Kafrelsheikh University · Sites in Egypt
Ages 12+
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 2–11
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2016; this study’s year is marked. 1 started in 2021.
This study's enrollment of 60 is above the median of 36 across 265 interventional studies indexed under Vitiligo.
Median enrollment 90 across the 14 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 14 have an industry lead sponsor. The 6 most frequent:
Incyte Corporation is the lead sponsor of 288 studies on the registry; 34 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
12 studies in Vitiligo by Incyte Corporation: 2 open now, 4 under way, 4 of them phase 3. Of 8 finished, 8 (100%) have results posted.
Among the 12 studies in Vitiligo by Incyte Corporation, this one is the 10th largest by enrollment, is one of 2 that started in 2021, is one of 5 in phase 2, and was the 6th registered.
Incyte Corporation’s Vitiligo studies by the year they started, since 2017.
2 of the studies testing ruxolitinib in Vitiligo that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804811Phase 3Incyte CorporationA Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo | 2027-04-30 |
| NCT07909668Kafrelsheikh UniversityTopical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo | 2026-12-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies testing ruxolitinib in Vitiligo, from their registry updates:
Among Incyte Corporation’s 12 in Vitiligo:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib cream will be administered twice a day (BID) for 24 weeks
Drug: Ruxolitinib cream
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Drug: Vehicle Cream
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Also known as: INCB018424 cream
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.
Also known as: Placebo
Percentage Change From Baseline in Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an Immune Biomarker, at Week 4, Week 12, and Week 24
Baseline was defined as the last non-missing measurement obtained on or before the first application of study drug. Percentage change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value)\*100.
Time frame: Baseline; Week 4, Week 12, and Week 24
Correlation of Key Skin Inflammatory Biomarkers of Vitiligo in Target Lesions to Efficacy Readouts
Clinical scores (facial Vitiligo Area Scoring Index \[F-VASI\] and total body Vitiligo Area Scoring Index \[T-VASI\]) were evaluated for correlation with skin CXCL10 levels.
Time frame: Baseline, Week 12, and Week 24
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)
Number of Participants With TEAEs During the Treatment-Extension Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days
Number of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.
Time frame: from the time of Informed Consent Form signing until the start of the Treatment-Extension Period or 30 days after the last application of study drug during the Double-Blind Period (up to Week 24 + 30 days)
Number of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the CTCAE, version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.
Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug at Week 52 + 30 days
| Milestone | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Started | 41 | 19 | 0 | 0 |
| Completed | 37 | 14 | 0 | 0 |
| Not completed | 4 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 3 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 0 |
| Milestone | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Started | 0 | 0 | 37 | 14 |
| Completed | 0 | 0 | 27 | 9 |
| Not completed | 0 | 0 | 10 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 5 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 |
| Withdrew: Participant refused safety follow-up | 0 | 0 | 3 | 2 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 |
Baseline was defined as the last non-missing measurement obtained on or before the first application of study drug. Percentage change from Baseline was calculated as the (\[post-Baseline value minus the Baseline value\] / Baseline value)\*100.
| percent change | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|---|---|
| Week 4 | -20.93 ± 36.216 | 8.13 ± 52.491 | — | — |
| Week 12 | -18.33 ± 40.035 | 21.13 ± 70.690 | — | — |
| Week 24 | -12.92 ± 46.146 | 22.17 ± 68.893 | — | — |
Clinical scores (facial Vitiligo Area Scoring Index \[F-VASI\] and total body Vitiligo Area Scoring Index \[T-VASI\]) were evaluated for correlation with skin CXCL10 levels.
| correlation coefficient | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| F-VASI | -0.34 | 0.15 |
| T-VASI | -0.43 | 0.02 |
An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period | 19 | 7 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.
| Participants | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Number of Participants With TEAEs During the Treatment-Extension Period | 12 | 3 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.
| Participants | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID |
|---|---|---|
| Number of Participants With a Grade 3 or Higher TEAE During the Double-Blind Period | 1 | 0 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug. AE severity was assessed per the CTCAE, version 5.0: Grade 1: mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment not indicated; Grade 2: moderate; minimal, local, or noninvasive treatment indicated; limiting age-appropriate activities of daily living; Grade 3: severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living; Grade 4: life-threatening consequences; urgent treatment indicated; Grade 5: fatal.
| Participants | Treatment-Extension Period: Ruxolitinib Cream 1.5% BID | Treatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID |
|---|---|---|
| Number of Participants With a Grade 3 or Higher TEAE During the Treatment-Extension Period | 0 | 1 |
Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 52 + 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib Cream 1.5% BID | 0/55 (0%) | 1/55 (1.8%) | 10/55 (18.2%) |
| Vehicle Cream BID | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| Event | Ruxolitinib Cream 1.5% BID | Vehicle Cream BID |
|---|---|---|
| Acute coronary syndromeCardiac disorders | 1/55 | 0/19 |
| Event | Ruxolitinib Cream 1.5% BID | Vehicle Cream BID |
|---|---|---|
| COVID-19Infections and infestations | 9/55 | 2/19 |
| Application site exfoliationGeneral disorders | 1/55 | 1/19 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/55 | 1/19 |
| GastroenteritisInfections and infestations | 0/55 | 1/19 |
| HydroceleCongenital, familial and genetic disorders | 0/55 | 1/19 |
| Seborrhoeic keratosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/55 | 1/19 |
| Urinary tract infectionInfections and infestations | 0/55 | 1/19 |
| Age, Continuous(years) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 45.1 ± 12.73 | 43.7 ± 13.16 | 44.7 ± 12.77 |
| Sex: Female, Male(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Female | 18 | 8 | 26 |
| Male | 23 | 11 | 34 |
| Ethnicity (NIH/OMB)(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 4 | 12 |
| Not Hispanic or Latino | 30 | 14 | 44 |
| Unknown or Not Reported | 3 | 1 | 4 |
| Race/Ethnicity, Customized(Participants) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| White/Caucasian | 25 | 13 | 38 |
| Black/African-American | 4 | 2 | 6 |
| Asian | 5 | 3 | 8 |
| Native Hawaiian/Pacific Islander | 1 | 0 | 1 |
| Not Reported | 5 | 0 | 5 |
| South Asian | 1 | 0 | 1 |
| Middle Eastern | 0 | 1 | 1 |
| Chemokine (C-X-C Motif) Ligand 10 (CXCL10), an immune biomarker(nanograms per Liter (ng/L)) | Double-Blind Period: Ruxolitinib Cream 1.5% BID | Double-Blind Period: Vehicle Cream BID | Total |
|---|---|---|---|
| Mean | 600.066 ± 959.3097 | 415.471 ± 177.4902 | 542.778 ± 804.0389 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
Supporting information: Study protocol, Statistical analysis plan
Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Data sharing details ↗ · www.incyte.com
Ran from Jun 2021 to primary completion in Nov 2022, 16 months.
Results were first posted in Dec 2023, 1 year after primary completion.
Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's 16 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib